Intratumoral (i.t.) administration of cytokine genes expressed by viral vectors represents a rational approach that induces cytokine secretion at the site they are needed, and i.t. vaccinia virus (VV) has shown promise in mesothelioma patients. However, we and others have shown that the mesothelioma tumor microenvironment includes macrophages, dendritic cells (DCs), and T cells. Therefore, we investigated which of these cell types are infected after exposure to VV or Fowlpox virus (FPV)-cytokine gene constructs. In vitro studies showed that mesothelioma tumor cells were resistant to FPV infection yet highly permissive to infection by VV vectors resulting in significant cytokine production and impaired proliferation. Macrophages secreted low levels of cytokine suggestive of resistance to overt infection. DCs transiently secreted virally derived cytokines, but did not mature during VV infection. VV inhibition of T cell proliferation was rescued by the interleukin (IL)-2 and IL-12 VV constructs. In vivo studies of murine mesotheliomas showed that i.t. injection of the parent VV could not hinder tumor progression. In contrast, the VV-cytokine constructs induced profound tumor regression. These data suggest that i.t. VV-cytokine gene constructs retard tumor growth by infecting mesothelioma cells and targeting the immune system through tumor-infiltrating DC and T cells.
Introduction
A number of strategies have been used in an effort to boost anti-tumor immunity in cancer patients. Often these strategies involved cytokines on account of the substantial body of literature showing that cytokines, such as interleukin (IL)-2, can have powerful anti-tumor effects in vivo. However, intravenous delivery is associated with numerous problems including short half-life, the ability to only function at short distances, and toxic side effects. Therefore, correct application with regard to dosage, time, and mode of administration is required.
One approach that may reduce systemic toxicity and maintain high levels of cytokine at local sites is to construct a viral vector that expresses DNA coding for cytokine production and inject it directly into the tumor site. [1] [2] [3] [4] [5] The viruses introduce this genetic code into infected host cells, which then produce the cytokine. A number of cytokine-gene viral vectors have been designed and include adenoviruses, retroviruses, lentiviruses, and pox viruses. [6] [7] [8] [9] [10] [11] However, each viral vector offers specific advantages; the potential of pox viral vectors, specifically vaccinia vectors, in mesothelioma has been already shown. 12 To this effect, a phase I gene therapy trial in malignant mesothelioma patients involving weekly intratumoral (i.t.) injections of a replication-restricted vaccinia virus-IL-2 (VV-IL-2) vector was conducted 12 showing the feasibility and safety of such an approach. Despite the generation of an anti-VV antibody response, VV-IL-2 mRNA gene expression persisted in tumor biopsies for up to 3 weeks and induced a local T cell infiltrate. However, no tumor regression was observed suggesting that the optimum therapeutic regimen has not yet been identified. We earlier considered that an alternative therapeutic strategy could be one that returned ex vivo dendritic cell (DC) infected in vitro with VV-IL-2 back to patients. However, we found that this approach downregulated antigen-presenting function in mature DC and was likely to be unreliable. 13 Thus, cytokine-armed DC may not be an effective alternative therapy and, as suggested by studies in mesothelioma and other cancers, regardless of the vector used, the direct i.t. approach remains a viable proposition. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Despite the apparent safety of the mesothelioma VV clinical trial, 12 safety issues continue to be a concern. Another member of the Poxviridae family, Fowlpox virus (FPV), undergoes abortive replication in the cytoplasm of mammalian cells allowing for transcription of inserted genes without production of functional FPV particles, thereby reducing safety concerns. 24 Several clinical trials using avipox recombinant vaccines have confirmed the safety and feasibility of this viral vector and, where a tumor antigen was encoded, have shown the induction of anti-tumor immunity mediated by CTL cells. [25] [26] [27] [28] However, VV may be particularly effective because it can infect a wide range of human and murine cells, leading to highly efficient expression of foreign genes. 19, 28, 29 VV does not integrate into cellular DNA, but replicates within the cytoplasm and contains all the enzymes necessary for efficient mRNA synthesis and translation. 30, 31 The VV constructs used are attenuated and tumor selective because of the insertion of cytokine genes into the thymidine kinase (TK) region. 32 Thus, in this study we compared VV and FPV viral vectors, both of which express the same marker antigen (hemagglutinin, HA). [24] [25] [26] [27] As both IL-2 and IL-12 have been shown to induce anti-tumor immunity against mesothelioma, [33] [34] [35] [36] [37] we compared VV with FPV vectors that encode either IL-2 or IL-12. We show here that i.t. injection of the IL-2 and/ or IL-12 VV gene constructs into murine mesotheliomas provided significant survival benefits in vivo. We also examined the effects the VV-cytokine gene constructs have on immune cells that infiltrate the tumor microenvironment (T cells, macrophages, and DCs), as well as on tumor cells.
Materials and methods

Mice
Female C57BL/6J mice aged 6-8 weeks were obtained from the Animal Resources Centre (Perth, Western Australia) and maintained under standard animal housing conditions. All mice were used in accordance with institutional guidelines and approval of the University of Western Australia and Curtin University's Animal Ethics Committees.
Murine tumor cell lines AE17 mesothelioma cell lines were derived from the peritoneal cavity of C57BL/6J injected with asbestos (crocidolite) fibers. Injection of AE17 into naı¨ve mice results in mesothelioma tumors histologically similar to human mesothelioma, as described earlier. 35 AE17sOVA was developed by transfecting the AE17 parental cell line with cDNA coding for sOVA, as described earlier. 35 Both cell lines were maintained in media, which consisted of RPMI 1640 (Invitrogen, Auckland, New Zealand) supplemented with 10% turbo bovine serum (Invitrogen), 50 mg ml -1 gentamicin (Pharmacia, Bentley, Australia), 60 mg ml -1 benzylpenicillin (CSL, Melbourne, Australia), and 0.05 mM 2-mercaptoethanol (Merck, West Point, PA). Transfected tumor cell lines were maintained in the same medium supplemented with 400 mg l -1 neomycin analog G418 (geneticin, Invitrogen). Cells were cultured at 37 1C in a 5% CO 2 humidified atmosphere; 143BTK
À is a human fibroblast osteosarcoma cell line lacking the TK gene (kindly donated by Jane Allen, Department of Microbiology, University of Western Australia) and was used for propagating all of the viral constructs. The 143BTK À cells were maintained in minimum essential media with L-glutamine (GIBCO BRL, NY) supplemented with 10% fetal calf serum (FCS), gentamicin, and benzylpenicillin.
Cytokine constructs FPV and VV-cytokine constructs were kindly donated by Ian Ramshaw (John Curtin School for Medical Research, Australian National University, Australia). Construction of rFPV by homologous recombination has been described earlier. 38 Briefly, FPV insertion plasmids were constructed containing either the HA gene or a cytokine (IL-2 or IL-12) gene and co-transfected into FPV-infected chicken embryo cells resulting in rFPV vectors containing both genes. Construction of rVV has also been described earlier 32 and was similar to the construction of rFPV vectors. Briefly, plasmid transfer vectors expressing either HA or the herpes simplex virus TK gene and cytokine were inserted into the VV-TK gene. Therefore, only viral products, which go through homologous recombination will have herpes simplex virus TK and will be produced in TK À cells. For TK selection, co-transfection of 143BTK À cells with the two plasmids results in rVV constructs expressing HA and cytokine. A control virus expressing HA alone was similarly constructed. 32, 38 Growth of VV constructs involved confluent 143BTK À cells infected with 1 Â 10 9 plaque-forming units (pfus) VV constructs, incubated for 2 h, and overlayed with 15 ml minimum essential media/2.5% FCS. After 3 days, cells were removed, washed in phosphate-buffered saline (PBS), and lysed by three freeze-thaw cycles. Concentrations of virus stocks were assessed using a plaque-forming assay in which confluent 143BTK À cells incubated with virus constructs for 1 to 2 h at 37 1C, were overlayed with minimum essential media/2.5% FCS, and incubated for 2 days. Crystal violet (Sigma, St Louis, MO) was used to visualize plaques. The pfus were determined based on the following formula: pfus per ml ¼ number of plaques Â volume Â dilution. Use of these viruses was approved of by the Genetic Manipulation Association Committee and the Office of Gene Technology Regulator. The antibodies used were CD11c-PE directed against the integrin a-chain of CD11c on murine DCs (clone HC3), CD54, CD80 directed against murine B7.1 (clone 1G10), CD86 directed against murine B7.2 (clone GL1), plus the isotype controls rat IgG2 a (clone R35-95), rat IgG2 b (clone A95-1), and Hamster IgG (clone A19-4), all from PharMingen (San Diego, CA). N418 (anti-CD11c) and TIB-120 (anti-murine MHC class II) were gifts from Professor P Holt, Perth. F4/80-biotin (ImmunoKontact Abingdon, UK) and Streptavidin-FITC (Amersham, UK) were also used. recombinant murine IL-2 (rec IL-2; PharMingen) all in 100 ml were added to the first well of 96-well plates (Falcon, Becton/Dickinson) in triplicate and then serially diluted one in two; 1 Â 10 5 whole splenocytes were then added to each well in 100 ml. Splenocytes were added alone or were stimulated with 2.5 mg ml -1 ConcanalavinA (ConA) (Sigma).
Cell preparations
IL-2 and IL-12 ELISA
The primary anti-cytokine capture antibody was added to 96-well MicroTest III flexible assay plates (Falcon, Becton/Dickinson) and incubated for 1 h at 37 1C (IL-2) or overnight at 4 1C (for IL-12), washed, blocked with 1% bovine serum albumin for 1 h at 37 1C, washed, and samples added. Standards of rmIL-2 (PharMingen) or IL-12 (gift from Dr Wolf, Genetics Institute Massachusetts) were serially diluted. Samples and standards were incubated overnight at 4 1C, washed, and the appropriate biotin anti-cytokine antibody added (anti-IL-2: PharMingen or C17.8-biotin anti-cytokine detection antibody; kindly donated by Dr Trinchieri, Philadelphia) and incubated for 30 min at 37 1C. This was followed by incubation with extravidin alkaline phosphatase conjugate for 30 min at 37 1C, washing, and addition of color substrate using phosphatase substrate tablets (Sigma, prepared according to manufacturer's instructions) and incubated for 30-60 min at 37 1C. Cytokine levels were determined by a Spectromax 250 spectrophotometer reading absorbance at 405 nm, using Softmax Pro V2.2.1 software (both Molecular Devices).
Cytotoxic T cell line assay to determine the biological activity of IL-2
The bioactivity of recombinant murine IL-2 and of IL-2 secreted from VV and FPV-infected cells was assayed using a murine IL-2-dependent cytotoxic T cell line (CTLL), as described earlier. 40 Briefly, 1 Â 10 4 CTLL cells per well/50 ml were plated with 50 ml of varying concentrations of rec IL-2 and test supernatants. CTLL proliferation was determined 24 h later by [ 3 H]-thymidine incorporation (for 5 h) and measured by liquid scintillation counting (Hewlett Packard, Palo Alto, CA). Activity was measured as the median effective dose (ED50; U ml -1 ) in which 1U is the amount required for 50% maximum growth from 1 Â 10 4 CTLL cells in 0.1 ml culture volumes during a 24-h culture period.
Statistical analysis
One way analysis of variance was used to compare cytokine production from VV or FPV-infected cells, or the mean 3 H-Thymidine incorporation, within each group across the different groups using GraphPad Prism (San Diego, CA).
Results
Mesothelioma cells are resistant to infection by FPV viral constructs
We first examined the ability of the FPV-HA and FPV-HA cytokine constructs to infect 143BTK À cells in vitro. 
Mesothelioma cells are permissive to VV infection
As we have already shown that the VV constructs readily infect 143BTK
À cells, 13 we next examined the ability of the VV-HA viral vector and its cytokine constructs to or 5 Â 10 6 pfus of the FPV constructs for 24 h (representative histograms of FPV-HA shown in (a) was detected using a biotinylated anti-HA antibody linked to streptavidin-PE. Pooled data is from one experiment using 1 Â 10 6 pfus of the FPV constructs (b) showing the percent of cells that were HA þ . AE17 mesothelioma tumor cells were similarly incubated with the FPV constructs for 24, 48, and 72 h and stained for HA expression; representative histograms in (c) and (d), and pooled data using 1 Â 10 7 pfus from three experiments shown in (e) as mean±s.d.
Cytokine-armed vaccinia can cure mesothelioma C Jackaman and DJ Nelson infect 1 Â 10 6 mesothelioma tumor cells in vitro. AE17 mesothelioma cells were incubated with 5 Â 10 6 or 1 Â 10 6 pfus of the VV constructs for 24, 48, or 72 h (Figures 2a-c) . All of the VV constructs led to 480% of AE17 mesothelioma cells being infected after 72 h in culture. The infectious nature of VV is further highlighted by the lack of titratable HA expression; that is 5 Â 10 6 pfus showed similar HA expression to 1 Â 10 6 pfus ( Figure 2 ). Closer examination of the ability of the FPV versus VV vectors to infect AE17 mesothelioma cells shows that none of the FPV constructs reached the same HA expression levels as their VV counterparts (Figures 2d-h) . Furthermore, FPV infection had little impact on AE17 cell viability except at the high 10 7 pfu dose (Figure 2i) . In contrast, all of the VV vectors reduced AE17 viability at a log fold lower dose by around 20% (Figure 2j ). However, this is less than the percent of cells that were infected (470%; Figure 2c) .
The data from Figures 1 and 2 show that while FPV readily infects 143BTK
À cells, it cannot reproduce this in AE17 mesothelioma cells, suggesting mechanistic differences with o30% of mesothelioma cells infected by FPVcytokine gene constructs at any time point. In contrast, 143BTK
À cells and mesothelioma cells were highly susceptible to VV infection. In the latter case, 480% of AE17 MM cells were infected after 72 h incubation with VV constructs. Thus, the following series of experiments focussed on the VV constructs.
VV-infected mesothelioma cells secrete high levels of the transfected cytokine VV-infected AE17 mesothelioma cells and 143BTK
À cells secreted both IL-2 and IL-12 (Figures 3a and b) . Neither cell type secreted endogenous IL-2 or IL-12 after VV-HA infection (Figures 3a and b) .
VV-infected mesothelioma cells are unable to proliferate AE17 cells readily proliferate in vitro in complete media (shown as no VV in Figure 4) . However, the presence of each VV construct prevented normal cell turnover. Log fold reductions of each VV construct restored this proliferative response. These data suggest that AE17 tumor cells are either lysed by VV or their ability to proliferate is impaired, both occurring as HA surface expression is still detectable on viable AE17 cell 3 days after VV infection. However, cells expressing HA also showed increased granularity and reduced size relative to uninfected cells indicative of cell death (data not shown).
Macrophages can be infected by VV
The next series of experiments were designed to better understand the events that may occur in vivo after i.t. administration of VV as per a recent clinical trial. 12 Macrophages dominate the AE17-induced tumor microenvironment and can represent up to 60% of the total tumor cellularity. [41] [42] [43] Therefore, these cells are highly likely to encounter any viral vector that is delivered by i.t. 5 pfus of the VV-HA cytokine constructs for 24 h. As removal of adherent macrophages using trypsin or cell scrapers led to high levels of cell death, only IL-2 and IL-12 cytokine levels in supernatants were analyzed (Table 1) . Overall levels of cytokine production were low relative to those secreted by infected mesothelioma cells. These data suggest that macrophages may be infected by VV at low levels.
VV-infected T cells require exogenous cytokines to restore proliferative responses T cells are recognized to be critical anti-tumor effector cells, and their proliferation may be directly provoked by increased i.t. IL-2 levels, 35 or indirectly by increased 'danger' levels and/or local IL-12 concentration that impact on antigen-presenting cells. 36 Thus, we examined splenic cells (as indicators of T cells) exposed to each of the VV constructs. IL-2 production by VV-HA-IL-2-infected spleen cells titrated in accordance with virus concentration (Table 2 ). Similar to IL-2, IL-12 production by T cells infected with VV-HA-IL-12 corresponded to viral load and increased with time ( Table 2) .
None of the constructs, including VV-HA-IL-2, induced proliferation of resting, non-activated splenic T cells (data not shown), despite IL-2 production by VV-HA-IL-2-infected cells. A CTLL assay confirmed that this virally derived IL2 was biologically active, as the IL-2-dependent CTLL cell line proliferated in response to supernatants from 143BTK À cells infected with VV-HA-IL-2, but not to VV-HA or VV-HA-IL-12 (data not shown).
ConA-induced splenic T cell proliferation was significantly inhibited at a high m.o.i. (10:1) of the VV-HA constructs ( Figure 5 ). This inhibition was ameliorated by the VV-cytokine constructs, regardless of whether the cytokine was IL-2 or IL-12.
VV constructs prevent DC maturation Finally, DCs were examined on account of the crucial function they have in inducing immune responses and they represent approximately 12% of cells in the AE17-induced tumor microenvironment, 41 thus they may be directly infected after i.t. administration of the VV constructs. In these studies, bone marrow-derived CD11c þ DCs (Figure 6a ) incubated with varying concentrations of the VV constructs did not express HA at 24 h (Figure 6b ). Similar results were seen for VV-cytokine gene constructs (data not shown). However, DCs exposed to the VV-cytokine constructs did produce cytokines (Table 3) indicative of infection. The cytokine levels titrated according to the pfus added, peaked at 24 h, and were higher than those secreted by macrophages. DC viability was compromised by high doses of VV-HA and VV-IL-12, but not by VV-IL-2 ( Figure 6c ). No upregulation of MHC class II expression was seen in DC infected with any of the constructs 24 or 48 h after infection with 1 Â 10 7 pfus (Figures  6d-g ), suggesting impaired maturation (Figures 6g-j) . Reducing viral load by a log fold partially improved DC maturation.
Mesothelioma tumor growth is arrested after i.t. VV-IL-12
Established mesothelioma tumors were given repeated i.t. injections of the VV-HA and cytokine contructs in a Cytokine-armed vaccinia can cure mesothelioma C Jackaman and DJ Nelson regimen that mimicked the clinical trial.
12 VV-HA did not provide a beneficial effect, as the tumors continued to grow at a similar, or faster, rate than the PBS controls (Figures 7a and b) . In contrast, both VV-IL-2 and VV-IL-12 monotherapies slowed tumor growth rate. VV-IL-2 offered cures to 20% of mice, whereas VV-IL-12 cured 80% of mice. The combination of both cytokine constructs seemed to further slow tumor growth rate, 
Discussion
Earlier studies have shown that i.t. administration of cytokine VV vectors represents a safe and rational approach that can be used in mesothelioma patients. 5, 12 Those studies were premised on the hypothesis that after i.t. administration, tumor cells infected by the viral vector would produce the cytokine and modify the tumor microenvironment. However, most tumor microenvironments contain stromal elements that include different immune cell types. Therefore, in these studies, we aimed to identify which cell types located in the mesotheliomainduced tumor microenvironment are likely to be infected and what the consequences of this infection might be. We show, using our murine mesothelioma model, that while the parent VV vector readily infects mesothelioma tumor cells, in vivo tumor growth continues unimpeded The differences observed between the susceptibility of mesothelioma tumor cells to the two viral constructs could be due to the differences in replicative ability. FPV undergoes abortive replication in mammalian cells, whereas VV can undergo full replication, but is attenuated and others have shown that VV is more efficient at delivering IFNg-mediated protection than FPV. 45 It may also be that these viral constructs enter cells through different mechanisms resulting in differing intracellular pathways being used. We concluded from these data that VV was likely to be a more useful vector for i.t. studies in our animal model.
We then turned our attention to the stromal cells that are part of the mesothelioma-induced tumor microenvironment. F4/80 þ macrophages are the dominant cell type in this complex microenvironment and in this model represent 60% of total tumor cellularity, 41 and, therefore, have a high probability of encountering an intratumorally injected cytokine vector. We used peritoneal macrophages as surrogates for tumor-infiltrating macrophages and found that they secreted low levels of cytokine regardless of the vector used suggestive of resistance to overt VV or FPV infection. These data indicate that after i.t. administration of a VV-cytokine gene construct, tumor-residing macrophages are not likely to be significantly infected.
Other important stromal cells are DCs. DCs are crucial antigen-presenting cells and low numbers of DCs are present in mesothelioma tumors. 41 In these studies, bone marrow-derived CD11c þ DCs were examined. No HA was observed after 24 or 48 h incubation with each VV construct, suggesting that the DCs were not infected with VV. However, their cytokine production was greater than that observed with macrophages and splenocytes. These data imply that DCs were infected leading to transient cytokine production. Thus, proteosomal degradation may have prevented HA expression and resolved DC infection. However, in agreement with the earlier reports, DC maturation did not occur after infection by the VV constructs implying reduced antigen-presenting function [46] [47] [48] [49] and indicating a potentially detrimental bystander response after i.t. VV. Furthermore, we have earlier shown that these VV vectors prevent DC maturation, 13 whereas others have shown that DC viability is compromised after phagocytosing-killed neoplastic cells in the presence of MVA viral particles. 50 Similarly, our data show that high doses of the VV-HA and VV-IL-12 constructs produce increased DC death. In contrast, the presence of IL-2 protected DC viability, but not their maturation.
T cells can also be found in mesothelioma tumors; 41, 43 thus, they may also be infected after i.t. administration of a viral vector. T cells have an important function in antitumor immunity, and splenic cells were used as an indicator of T cell responsiveness to the viral constructs. VV-infected spleen cells produced low levels of cytokine. These data suggest that T cells, or other splenic components, are resistant to infection by VV. Nonetheless, biologically active IL-2 was produced by VV-HA-IL-2-infected cells. The most striking observation was that the VV-HA vector interfered with T cell proliferative responses to ConA. Similarly, others have reported a transient decrease in human T cell proliferative responses after vaccinia immunization. 51 However, T cell proliferation was restored by the IL-2 and IL-12 cytokine constructs. These data imply that use of a VV vector without the rescue effects of an appropriate cytokine may impair T cell immunity.
Taken together, these data show that after i.t. injection, VV vectors infect large numbers of mesothelioma tumors cells such that the tumor cells cease to cycle and undergo cell death. However, VV vectors also sabotage the immune system by preventing DC maturation and T cell proliferation. Indeed, i.t. injection of a VV vector without cytokine arming enables tumor progression. In contrast, VV-cytokine gene constructs infect large numbers of mesothelioma tumors cells, which are likely to generate a cytokine-rich microenvironment. Furthermore, tumorinfiltrating DCs and T cells may also be infected and secrete the same cytokines, albeit to a much lesser extent. Importantly, as a result of VV infection mesothelioma, tumor cells cease to cycle and those remaining viable may then be destroyed by T cells rescued by virally derived IL-2 and/or IL-12. Indeed, our in vivo studies show that both VV-cytokine gene constructs significantly restrained tumor growth. Their combination with a tumor antigen vaccination strategy may further improve this outcome. Thus, these proof-of-principle studies support the concept of using VV vectors to deliver cytokines into the mesothelioma tumor site.
